GH Research PLC Reports 2024 Financial Results and Clinical Progress

Gh Research Plc ( (GHRS) ) has released its Q4 earnings. Here is a breakdown of the information Gh Research Plc presented to its investors.

GH Research PLC is a clinical-stage biopharmaceutical company focused on developing innovative treatments for psychiatric and neurological disorders, particularly through its proprietary mebufotenin therapies for treatment-resistant depression (TRD).

In its latest earnings report, GH Research PLC provided a comprehensive update on its financial performance for 2024 and progress in clinical trials. The company highlighted significant advancements in its Phase 2b trial for GH001 in TRD, as well as ongoing efforts to address regulatory requirements for its proprietary aerosol delivery device.

The company’s Phase 2b trial for GH001 in TRD showed promising results, with the primary endpoint met and a significant reduction in depression scores compared to placebo. The trial demonstrated a high remission rate and good tolerability. Additionally, GH Research completed two Phase 2a proof-of-concept trials in postpartum depression and bipolar II disorder, both meeting their primary endpoints with significant reductions in depression scores.

Financially, GH Research reported a net loss of $39 million for 2024, with increased research and development expenses driven by clinical development activities. The company’s cash position remains strong, bolstered by proceeds from a recent public offering.

Looking ahead, GH Research remains focused on advancing its clinical programs and addressing regulatory requirements. The company is preparing to engage with the FDA to resolve the clinical hold on its GH001 IND, with a full response expected in mid-2025.